Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Marso SP, et al. Among authors: nissen se. Am Heart J. 2013 Nov;166(5):823-30.e5. doi: 10.1016/j.ahj.2013.07.012. Epub 2013 Oct 2. Am Heart J. 2013. PMID: 24176437 Free article. Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. Among authors: nissen se. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. White WB, et al. Among authors: nissen se. Am Heart J. 2011 Oct;162(4):620-626.e1. doi: 10.1016/j.ahj.2011.08.004. Epub 2011 Sep 14. Am Heart J. 2011. PMID: 21982652 Clinical Trial.
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. White WB, et al. Among authors: nissen se. N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2. N Engl J Med. 2013. PMID: 23992602 Free article. Clinical Trial.
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, Davey Smith G, Holman RR, Woodward M, Gupta A, Adler AI, Wamil M, Sattar N, Cushman WC, McManus RJ, Teo K, Davis BR, Chalmers J, Pepine CJ, Rahimi K; Blood Pressure Lowering Treatment Trialists' Collaboration. Nazarzadeh M, et al. Lancet Diabetes Endocrinol. 2022 Sep;10(9):645-654. doi: 10.1016/S2213-8587(22)00172-3. Epub 2022 Jul 22. Lancet Diabetes Endocrinol. 2022. PMID: 35878651 Free PMC article.
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif JC; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. Ridker PM, et al. Am Heart J. 2016 Aug;178:135-44. doi: 10.1016/j.ahj.2016.05.010. Epub 2016 May 28. Am Heart J. 2016. PMID: 27502861 Free article. Clinical Trial.
Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials.
Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes AC, Salam A, Dwyer JP, Farzadfar F, Sundström J, Woodward M, Davis BR, Rahimi K; Blood Pressure Lowering Treatment Trialists' Collaboration; Blood Pressure Lowering Treatment Trialists Collaboration. Canoy D, et al. Heart. 2022 Jul 27;108(16):1281-1289. doi: 10.1136/heartjnl-2021-320171. Heart. 2022. PMID: 35058294 Free PMC article.
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2021 Sep 18;398(10305):1053-1064. doi: 10.1016/S0140-6736(21)01921-8. Epub 2021 Aug 27. Lancet. 2021. PMID: 34461040 Free PMC article.
532 results